Biocon Biologics (BBL) is selling its dermatology and nephrology branded formulations business to Eris Lifesciences for Rs 366 crore. The deal includes the company’s small molecule brands and will result in over 120 employees transitioning to Eris. The divestment is in line with BBL’s strategy to focus on core therapy areas. Eris Lifesciences believes the acquisition will deliver value to shareholders.
